KURZPROTOKOLL
EU-RHAB

Öffentlicher Titel	Internationales Register für rhabdoide Tumoren jeder Lokalisation
Wissenschaftl. Titel	EUROPEAN RHABDOID REGISTRY A multinational registry for rhabdoid tumors of any anatomical site
Kurztitel	EU-RHAB
Studienart	multizentrisch, prospektiv, Therapiestudie, offen/unverblindet, Register, nicht-interventionelle Studie, Investigator Initiated Trial (IIT), mehrarmig
Studienphase	nicht zutreffend
Erkrankung	Kinder: andere Tumorerkrankungen: sonstige Studien
Ziele	- Creation of a comprehensive database for patients with rhabdoid tumors of any anatomical site diagnosed in European countries. - Development of a structured plan for central review of histology (including SMARCB1 immunhistochemistry) and molecular genetics. To improve (neuro-) pathological, clinical and molecular genetic characterization of rhabdoid tumors. - To render support to existing tumor banks and to perform biological studies, to identify future therapeutic targets. - To cooperate with: Groups specialized in pediatric Soft Tissue Sarcoma (e.g. CWS, EPSSG) and Nephroblastoma, in studying similarities between extra- (RTK and MRT) and intra-CNS (AT/RT) rhabdoid tumors and in defining common treatment elements used in AT/RT and extra-CNS rhabdoid tumours. To communicate with groups in the USA and Australia, to define points of reciprocal interest and potential for cooperation. - To determine event free and overall survival of patients. - To evaluate the time to progression in patients with rhabdoid tumors treated on a consensus therapeutic regimen. - To assess the importance of surgical technique, particularly the effect of complete surgical resection. - To assess the importance of involved field radiotherapy.
Einschlusskriterien	- Patients of any age with histologically proven rhabdoid tumors, verified by central pathology review - In general absence of nuclear SMARCB1 staining should have been demonstrated. However, as rhabdoid tumor cases without SMARCB1 mutations have been published, reference pathology may suggest inclusion of tumors with positive SMARCB1 staining, but unequivocal diagnostic criteria for histopathologic diagnosis of a rhabdoid tumor. - Patients that have been pretreated under the suspicion of a renal tumor (RTK), malignant tumor of the brain (e.g. glioblastoma, sPNET or medulloblastoma) (AT/RT) or soft tissue tumor (MRT) -  Informed consent of the legal guardians concerning data and tumor material transfer
Ausschlusskriterien	- Diagnoses other than rhabdoid tumors - Missing consent of the legal guardians.
Alter	Keine Altersbegrenzung
Prüfzentren	**Universitätsklinikum Frankfurt** (Ausgesetzt) Klinik für Kinder- und Jugendmedizin Theodor-Stern-Kai 7 60590 Frankfurt am Main Hana Schlottner Tel: 0 86710 Fax: 0 87735 Schlottner.Hana@kgu.de

Kinder- und Jugendmedizin (Ausgesetzt)
Schwerpunkt Onkologie, Hämatologie und Hämostaseologie
Theodor-Stern-Kai 7
60590 Frankfurt am Main
Hana Schlottner
Tel: 0 86710
Fax: 0 87735
Schlottner.Hana@kgu.de

Förderer Deutsche Kinderkrebsstiftung